JB Pharma Records Revenue Growth of 14 Percent to INR 896 Crores in Q1 FY24
For the first quarter of FY24 ended June 30, 2023, JB Pharma recorded revenue of INR 896 crores growing 14 percent from INR 785 crores in the corresponding quarter.
Global Pharma | 09/08/2023 | By Manvi | 1441
SK Pharmteco secures 12 global pharma clients sets up US R&D center
SK Pharmteco secures 12 global pharma clients, sets up US R&D center
Global Pharma | 09/08/2023 | By Sudeep Soparkar | 924
Pharma ULD firm Envirotainer invests in packaging co va-Q-tec
Pharma ULD firm Envirotainer will be combined with packaging company va-Q-tec following the latter’s majority purchase by EQT Private Equity.
Global Pharma | 08/08/2023 | By Sudeep Soparkar | 1213
Pharma manufacturer Kincell Bio secures US$36m in funding
Pharmaceutical manufacturer Kincell Bio has received US$36m in stealth funding, which was led by Kineticos Ventures.
Global Pharma | 07/08/2023 | By Sudeep Soparkar | 1022
Venus Remedies secures marketing authorisation for key cancer drugs from Philippines, Paraguay, Georgia and Moldova; strengthens global presence
Global Pharma | 01/08/2023 | By Sudeep Soparkar | 1117
Qualicaps, a renowned producer of hard capsules and pharmaceutical processing equipment for oral dosage, is part of the Mitsubishi Chemical Group
Global Pharma | 31/07/2023 | By Sudeep Soparkar | 923
Axplora Opens New cGMP Pilot Facility for Flow Chemistry
The new facility is part of the company’s investment in differentiated and specialized technologies.
Global Pharma | 26/07/2023 | By Manvi | 1093
Global Pharma | 21/07/2023 | By Sudeep Soparkar | 705
Vector Laboratories Acquires Quanta BioDesign to Continue Growth Strategy
Vector Laboratories Acquires Quanta BioDesign to Continue Growth Strategy
Global Pharma | 19/07/2023 | By Sudeep Soparkar | 707
Global Pharma | 17/07/2023 | By Sudeep Soparkar | 812
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy